Obesity is now recognised as a disease that is associated with serious morbidity and
increased mortality. One of its main metabolic complications is type 2 diabetes, as the two …

Insulin resistance (IR) and cardiovascular disease (CVD) represent two universal public
health hazards, especially in today's Western societies. A causal-effect relationship has …

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …

OBJECTIVE There is mounting evidence regarding the cardiovascular benefits of sodium–
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists …

Background Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has
demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). We …

Background: The goal of this work was to investigate trends (2001–2019) for cardiovascular
events and cardiometabolic risk factor levels in individuals with type 2 diabetes (T2D) and …

Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

Abstract Background In the Semaglutide Treatment Effect in People with obesity and HFpEF
(STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms …

Aim To test the hypothesis that glucagon‐like peptide‐1 receptor (GLP‐1R) agonists have
beneficial effects on vascular endothelial function, fibrinolysis and inflammation through …

Background Heart failure with preserved ejection fraction (HFpEF) is common in type 2
diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic …